Technology Transfer

Hoa Lac platform provides standard cGMP conditions for development of International transfer of cutting-edge technologies in the field of stem cells R&D- the leadership development strategy of HLPstem.

3D Cell Expandition & Printing-An Emerging Technique for Regenerative Cell-Based Therapies

The three-dimensional (3D) cell culture approach offe new potential in regeneration therapy. 3D culture technology is being used more and more in stem cells R&D do to its advantages in improving cell division and expansion rates, creating the cell growth and differentiation under microenvironment conditions that more closely resemble the in vivo conditions, enabling the fabrication of complex 3D mimicking living tissue/organs and establishing a cost-effective screening platform for Patient-Specific Organoid, Organ On Chip Model in drug development and testing.

Stem cell transplantation has been used effectively as a combination therapy in the treatment of leukemia in Vietnam. The automatic 3D culture technology transferred and developed by HLP is a solution for rapid cell expansion, safely and promptly meeting the current treatment needs of many patients.

iPS Stem cell- Meaningful framework for Organ Regeneration & Repair strategies 

Induced Pluripotent Stem Cell (iPSC) are a type of stem cell reprogramming somatic cells to enter an embryonic-like state. The first iPSC was created by Shinya Yamanaka in 2006 (Nobel Prize 2012). The advancements in iPSC technology have profound implications for regeneration medicine, in the fields of disease modeling, drug discovery, and personalized medicine, particularly in allogeneic stem cells transplantation, iPSCs provide a source of cells to replace or repair aged or damaged tissues, anti-aging and extending healthy lifespan.

HLP works closely with international partners who are conducting clinical trials using differentiated IPSC as a cutting-edge approach of in-situ tissue repair and regeneration directly within the body for treating liver diseases, neurological diseases and graft-versus-host diseases

Extracellular Vesicles - Ideal biomaterials for regenerative nanomedicine applications  

Extracellular vesicles (EVs) such as Exosomes are smallest cell-derived nanovesicles with a diameter ranging from 40 to 150 nm. EVs carry different particular membrane proteins, growth factor receptors, cell adhesion molecules and possess many advantages such as natural targeting ability, low immunogenicity, stability in body fluids and the ability to cross biological barriers. Exosomes have been utilized as low-cost production of high-quality living biomaterials for both diagnostic and therapeutic intentions. Therapeutic potentiality of exosomes for treatment od stroke, cancer, heart disease, neurodegenerative, cardiovascular, and orthopedic diseases have been exhibited in many preclinical studies .

HLP with its open cGMP platform will be the place for manufacturing VEs in various aspects of R&D. 

Stem cell-CRISPR-Cas9 Gene Editing : Cutting -Edge Cancer Figting Tools

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a revolutionary approach cancer treatment. T cells extracting a chimeric antigen receptor (CAR) that targets specific cancer cells can destroy cancer cells while sparing healthy cells. CAR-T was successfully used to treat certain aggressive blood cancers. Within 28 days of the CAR-T cell therapy, 50 percent of patients responded positively and around 80% to 90% of patients will go into remission after six months (Terry Fry, 2024, Massimo Martino et al, Front. Immunol., 02 May 2024). With the recent progress in automated CAR-T cell manufacturing facility the preparation of cells to be infused back into a patient can be ready within 14 days.

Six FDA-approved CAR T cell treatments are available, including the pioneering CRISPR-based clinical trials for treating sickle cell disease and beta-thalassemia.

 Photo from Congenital Ear Institute and  University of Wollongong in Australia

Photo: Robin L. Webb et al, Translational Stroke Research , 2018

Photo Medical College of  Wisconsin, Oct 5th, 2020